Compare Global X CleanTech (CTEC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Novartis AG — how do they compare? Global X CleanTech trades at $56.49, while Novartis AG trades at $149.88 (market cap $288.65B). The key difference: Novartis AG pays a 3.15% dividend while Global X CleanTech pays none, and Novartis AG is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| CTEC | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $168.62 |
52-Week Low | $39.45 | $113.50 |
Market Cap | — | $288.65B |
Enterprise Value | — | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $57.34, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure but oscillators showing potential oversold conditions. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. The company has announced a future dividend of $0.07 per share payable in July 2026, though recent earnings and cash flow data are not provided.
The outlook remains cautious due to weak technical momentum and incomplete financial disclosure. Investment opportunity hinges on upcoming financial results revealing profitability and growth, while risks include persistent selling pressure and lack of current fundamental visibility. Investors await clearer earnings updates to assess valuation and business health.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
